In recent years, there has been rapid progress in the field of pulmonary hypertension (PH). With the deeper understanding of the pathogenesis of PH, the increase of evidence-based medical evidence, the continuous updating of PH clinical classification, the hemodynamic diagnostic boundaries, and the emergence of new targeted drugs and interventions, the guidelines are constantly being updated. It brings new challenges to the standard diagnosis, treatment and comprehensive management of PH in China. Compared with the world, there are still many problems in the field of PH in China. The heterogeneity of PH causes the complexity of the disease and the difficulty of clinical management, and the early identification and diagnosis of pH face great challenges. Individualized and precise treatment needs to be further optimized, and standardized diagnosis and treatment strategies need to be popularized and promoted. In recent years, rapid progress has been made in the field of PH, including its pathogenesis, diagnostic thresholds, classification and comprehensive treatment methods, prompting an update of the guidelines, which brings a new level of standardized diagnosis and comprehensive management of PH in China. This guideline brings new challenges to the standardized diagnosis and treatment and comprehensive management of PH in China. Here, we discussed in depth the current situation of diagnosis and treatment in the field of PH, as well as the development of a standardized system for PH in China.
肺动脉高压（pulmonary hypertension，PH）领域近年来取得了迅猛的进展，随着对PH发病机制认识加深，循证医学证据不断增加，PH临床分类、血流动力学诊断界值不断更新、新的靶向药物和干预手段也不断出现，促使指南不断更新，为国内PH的规范诊疗和综合管理水平带来新的挑战。基于国际视角，我国在PH领域仍存在诸多问题，PH的异质性造成了疾病的复杂性和临床处理的困难，其早期识别与诊断面临巨大挑战，个体化、精准化治疗需要进一步优化，规范化和标准化诊治策略有待普及和推广。本文结合新版指南及最新进展，就国内PH领域诊疗现状和肺动脉高压标准化体系建设进行探讨。.